3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
3
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Thoracic
4
Tumor-Agnostic
3
Lymphoid
3
Gastrointestinal
3
Dermatologic
3
CNS
3
Breast
3
Head & Neck
2
Genitourinary
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Gynecologic
1
Endocrine
1
Classical hematology
1
Conditions
Neoplasm Metastasis
2
Neoplasms
1
Interventions
Surveys and Questionnaires
70
Blood Specimen Collection
48
Radiotherapy
39
Magnetic Resonance Spectroscopy
35
pembrolizumab
31
Gemcitabine
30
Bevacizumab
30
Nivolumab
29
Carboplatin
29
Radiosurgery
27
Standard of Care
26
Oxaliplatin
26
Capecitabine
25
Paclitaxel
24
Interviews as Topic
24
Cisplatin
24
Fluorouracil
23
Erlotinib Hydrochloride
22
Everolimus
19
Irinotecan
18
Trastuzumab
17
Methods
17
Exercise
17
Docetaxel
17
Biopsy
17
Cyclophosphamide
16
Educational Status
15
Sorafenib
14
Ipilimumab
14
Fluorodeoxyglucose F18
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
entrectinib
×
Tumor-Agnostic
×
Clear all
NCT05525858
2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
1,000 enrolled
NCT04817956
2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2
Recruiting
3,000 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled